Atlas Trials

Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II

Clinical trial NCT05385250 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05385250
Sponsor
Karen-Lise Garm Spindler
Status
ACTIVE_NOT_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Anal CancerRadiotherapy Side Effect
Start date
2021-08-23
Primary completion
2025-01-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.